|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||79.69 - 81.34|
|52-week range||55.69 - 86.31|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||78.27|
|Forward dividend & yield||0.33 (0.44%)|
|Ex-dividend date||10 May 2021|
|1y target est||N/A|
In this Motley Fool Live video recorded on Nov. 3, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether investors should have Lonza on their watchlists. Keith Speights: Brian, one final topic before we get to questions.
By Dhirendra Tripathi
ZURICH (Reuters) -Swiss contract drugmaker Lonza raised its 2021 outlook on Friday after booming business making ingredients for COVID-19 vaccines and strong growth elsewhere helped it beat analysts' expectations during the first half of the year. "In the prior year we provided an estimate for how much we expected from Moderna sales for 2021...the number is much higher given our ability to increase output at our existing facilities," Chief Financial Officer Rodolfo Savitzky told reporters. Its previous guidance had been for sales growth in the low double-digit range.